Safety and Efficacy of Metabolically Armed CD19 CAR-T Cells (Meta10-19) in the Treatment of r/r DLBCL Clinical Research
A Study of Metabolically Armed CD19 CAR-T Cells Therapy for Patients With Relapsed and/or Refractory Diffuse Large B-Cell Lymphoma
Trial Details
- NCT ID
- NCT06120166
- Phase
- EARLY_PHASE1
- Sponsor
- He Huang
- Status
- RECRUITING
- Cancer Type
- Diffuse Large B-Cell (DLBCL) Lymphoma
- Interventions
- Metabolically Armed CD19 CAR-T cells
- Locations (sample)
- Hangzhou, Zhejiang, China|30.29365,120.16142
Key Eligibility Criteria
- The patient or his/her guardian voluntarily signed the informed consent
- Adult Patients clinical diagnosis of relapsed and refractory diffuse large B-cell lymphoma (Primary mediastinal large B-cell lymphoma and transform…
- Definition of refractory:
- No response to the last treatment, including:
For full eligibility, visit ClinicalTrials.gov.